Strides Pharma Science Limited, headquartered in Bengaluru, India, is a prominent pharmaceutical company specialising in the manufacturing of pharmaceutical products, over-the-counter (OTC) drugs, and nutraceuticals. Its diverse product portfolio includes soft gel capsules, hard-gel capsules, tablets, as well as dry and wet injectables.
On January 20, 2025, Strides Pharma announced that its step-down wholly-owned subsidiary, Strides Pharma Global Pte. Ltd., Singapore, has received a coveted approval from the United States Food and Drug Administration (USFDA) for its Acetaminophen and Ibuprofen tablets (125 mg/250 mg, OTC).
The company confirmed that this product is bioequivalent to the reference listed drug, Advil Dual Action with Acetaminophen (125 mg/250 mg, OTC), marketed by Haleon US Holdings LLC.
This milestone further enriches Strides Pharma’s portfolio of OTC products, the company stated. “By introducing a dual-action pain relief option, we aspire to cater to a wider patient demographic, delivering effective and accessible solutions for pain management,” said a company representative.
The tablets will be manufactured at the company’s state-of-the-art flagship facility in KRSG, Bengaluru.
The combination of Acetaminophen and Ibuprofen offers relief from a variety of ailments, including headaches, dental pain, menstrual cramps, muscle aches, and arthritis.
“Ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), works synergistically in this formulation by inhibiting the body’s production of natural substances responsible for inflammation. This action effectively reduces swelling, pain, and fever,” the company explained.
Strides Pharma reported a strong turnaround in Q2 FY25, posting a net profit of ₹93.7 crore compared to a net loss of ₹149.45 crore in the same period last year.
Revenue from operations grew 20% YoY to ₹1,201.11 crore, driven by new product launches and a 26.2% surge in US revenues to $75 million. EBITDA rose 31% to ₹235.8 crore, with margins improving to 19.6% from 17.5% a year ago.
At 10:22 AM today, Strides Pharma Science Limited shares traded at ₹586.00 per share on the NSE.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Jan 21, 2025, 2:12 PM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
